Abstract
Roscovitine induced apoptosis in isolated B-chronic lymphocytic leukemia cells of 25 patients of whom nine with relapsed and seven with fludarabine-refractory disease. It was synergistic with alemtuzumab and restored sensitivity to alemtuzumab in initially alemtuzumab-resistant samples. Observed roscovitine-induced up-regulation of CD52 surface expression may be one of the underlying mechanisms for this synergism.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Alemtuzumab
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / administration & dosage
-
Antigens, CD / metabolism
-
Antigens, Neoplasm / metabolism
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Apoptosis / drug effects*
-
CD52 Antigen
-
Cohort Studies
-
Drug Synergism*
-
Female
-
Glycoproteins / metabolism
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Male
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Purines / administration & dosage
-
Roscovitine
-
Salvage Therapy
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antigens, CD
-
Antigens, Neoplasm
-
CD52 Antigen
-
CD52 protein, human
-
Glycoproteins
-
Purines
-
Roscovitine
-
Alemtuzumab
-
Mitoxantrone